{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["92(13)"],"submitter":["Trenkwalder C"],"pubmed_abstract":["OBJECTIVE:To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve \"off\" time in fluctuating Parkinson disease (PD) compared to the standard combination of 4:1 levodopa/carbidopa with the usual 200 mg of entacapone (LCE) during a 4-week treatment period. METHODS:This was a randomized, double-blind, double-dummy, active-controlled, crossover, multicenter, phase II, proof-of-concept study in patients with fluctuating PD. RESULTS:One hundred seventeen patients were randomized into the study (mean age 67.0 years; daily \"off\" time 5.3 hours; mean daily levodopa dose 610 mg). Carryover-adjusted mean changes from baseline \"off\" times were during ODM-101/65, -1."],"journal":["Neurology"],"pagination":["e1487-e1496"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6453771"],"repository":["biostudies-literature"],"pubmed_title":["Increased dose of carbidopa with levodopa and entacapone improves \"off\" time in a randomized trial."],"pmcid":["PMC6453771"],"pubmed_authors":["Vahteristo M","Ellmen J","Trenkwalder C","Kuoppamaki M","Muller T"],"additional_accession":[]},"is_claimable":false,"name":"Increased dose of carbidopa with levodopa and entacapone improves \"off\" time in a randomized trial.","description":"OBJECTIVE:To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve \"off\" time in fluctuating Parkinson disease (PD) compared to the standard combination of 4:1 levodopa/carbidopa with the usual 200 mg of entacapone (LCE) during a 4-week treatment period. METHODS:This was a randomized, double-blind, double-dummy, active-controlled, crossover, multicenter, phase II, proof-of-concept study in patients with fluctuating PD. RESULTS:One hundred seventeen patients were randomized into the study (mean age 67.0 years; daily \"off\" time 5.3 hours; mean daily levodopa dose 610 mg). Carryover-adjusted mean changes from baseline \"off\" times were during ODM-101/65, -1.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2025-04-04T23:59:36.007Z","creation":"2019-06-06T22:54:47Z"},"accession":"S-EPMC6453771","cross_references":{"pubmed":["30824559"],"doi":["10.1212/WNL.0000000000007173"]}}